Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a major limiting side effect of many
common chemotherapeutics often leading patients to terminate their chemotherapy …

Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by a variety of
symptoms including paresthesia, numbness, burning pain, allodynia and hyperalgesia …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition
in patients undergoing treatment with commonly used agents such as platinum compounds …

Purpose: Treatment of chemotherapy-induced peripheral neuropathy (CIPN) is challenging
for clinicians, and many clinical trials and meta-analyses on CIPN are controversial. There …

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious and often persistent
adverse consequence of certain chemotherapeutic agents. It is a major dose-limiting factor …

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of
many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome …

Introduction: Chemotherapy-induced peripheral neuropathy (CIPN), a common adverse
effect of several chemotherapeutic agents, has a significant impact on quality of life and may …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …